ARIUS PHARMACEUTICALS
Arius Pharmaceuticals is a healthcare company that operates as a specialty pharmaceutical company which develops and commercializes supportive care prescription products for the treatment of acute conditions common to surgical and cancer patients, such as pain, nausea, and vomiting. The company was founded in 2003 by Mark A. Sirgo and Andrew L. Finn and it is located in the United States.
ARIUS PHARMACEUTICALS
Industry:
Health Care
Address:
Morrisville, North Carolina, United States
Country:
United States
Status:
Active
Similar Organizations
Ansan Pharmaceuticals
Ansan Pharmaceuticals is a Health Care company.
Aryx Pharmaceuticals
Aryx Pharmaceuticals is a Health Care company.
MedPointe Pharmaceuticals
MedPointe Pharmaceuticals is a Health Care company.
Founder
More informations about "Arius Pharmaceuticals"
Arius Pharmaceuticals - PitchBook
Arius Pharmaceuticals General Information Description. Developer of pharmaceutical products. The company engages in providing drugs, medial supplies and equipment, pharmaceuticals …See details»
Arius Pharmaceuticals Inc - Company Profile and News
Company profile page for Arius Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
Arius Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Arius Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Mark Sirgo: Positions, Relations and Network - MarketScreener
Oct 30, 2024 Sirgo was the founder of Arius Pharmaceuticals, Inc. (founded in 2003) where he held the title of Chief Executive Officer in 2004. ... Corium Pharma Solutions, Inc. is a full …See details»
Roche buys Canadian biotech firm Arius - The Toronto Star
Jul 23, 2008 BASEL, Switzerland Pharmaceutical giant Roche Holding on Wednesday announced plans to buy Arius Research Inc. of Canada for C$191 million as the latest in a …See details»
Arius Research - Crunchbase Company Profile & Funding
Jan 17, 2015 ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company …See details»
Arius Research Company Profile 2024: Valuation, Investors
Arius Research General Information Description. Developer of anticancer monoclonal antibodies therapeutics. The company offers a proprietary technology platform that identifies monoclonal …See details»
BioDelivery Sciences International, Inc. Announces the Closing of …
Aug 24, 2004 Contacts BioDelivery Sciences International, Inc., Newark Francis E. O'Donnell, Jr., M.D., 973/972-0015 or Arius Pharmaceuticals, Inc. Mark A. Sirgo, Pharm.D, 919-510 ...See details»
Arius Pharmaceuticals acquired by BioDelivery Sciences
Arius Pharmaceuticals Arius Pharmaceuticals is a Health Care company. Acquiring Organization: BioDelivery Sciences BioDelivery Sciences is a pharmaceutical company that focuses on pain …See details»
Leadership - Kisoji Biotechnology Inc.
Previously, he was the founder, C.S.O. and C.E.O. of ARIUS Research Inc., a publicly-traded biotechnology company developing therapeutic cancer antibodies and sold to Roche in 2008. …See details»
Roche starts acquisition process of ARIUS to gain access to new ...
Jul 23, 2008 Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics Roche and ARIUS Research Inc. today announced that the …See details»
Young, David S. - The Wall Street Transcript
Jan 10, 2005 Prior to founding ARIUS in 1999, he was a co-founder of Apogen Inc., a transplantation company, Vertis BioSciences Inc., a biotechnology company, and Diversified …See details»
Roche to Acquire Arius for C$191 Million | PHARMA JAPAN
Roche and Arius Research Inc. of Canada, which develops antibody screening technology, announced on July 23 that the two companies have signed a definitive agreement that allows …See details»
Roche Starts Acquisition Process Of ARIUS To Gain Access To New ...
Jul 24, 2008 Commenting on the transaction, David S. Young, President and Chief Executive Officer of ARIUS said: "Since founding ARIUS in 1999, we have focused on developing a truly …See details»
Toronto-based Arius scores big (and a win for investors)
Last week, MaRS Venture Group Director Veronika Litinski sat next to David Young at a pharma industry business function. David is a Founder and CEO of Arius Research (TSX: ARI) who …See details»
David Young, MD - BIO Investor Forum | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Dr. Young is the C.E.O., …See details»
Andrew L. Finn - Crunchbase Person Profile
Aug 1, 2004 He joined the company in August 2004 upon our acquisition of Arius Pharmaceuticals, of which he was a co-founder. Dr. Finn has previously served as our Senior …See details»
Arius Pharmaceuticals, Inc. Features Preclinical Data on ... - BioSpace
Sep 7, 2007 This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, …See details»
ARIUS Research Inc. - Toronto, Canada - bionity.com
Feb 20, 2008 ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, …See details»